Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy
OBJECTIVE: Merkel cell carcinoma (MCC) is a very rare and aggressive neuroendocrine skin cancer, characterized by a 5-year survival rate of 13.5% in patients with distant metastases. This study aimed to evaluate the cost-utility of retifanlimab compared to avelumab in the treatment of metastatic MCC...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd Medical Publishers
2025-03-01
|
| Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
| Subjects: | |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1574 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|